NovartisNVS announced that the European Commission (EC) has approved Revolade for the treatment of pediatric patients (aged 1 year and above) suffering from chronic immune (idiopathic) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback